Inovalon Results Presentation Deck

FY 2017 - Revenue Growth and Margin Expansion Growth Operating Leverage Continued Investment Revenue $427.6 FY 2016 62.8% Gross Margin FY 2016 $449.4 $27.1 FY 2017 FY 2016 66.4% Sales & Marketing $34.1 FY 2017 FY 2017 Adjusted EBITDA $109.0 $99.9 FY 2016 Adj. EBITDA Margin 24.3% 23.4% FY 2016 $62.4 FY 2017 Investment in Innovation $85.8 FY 2016 Note: All $ amounts are in Millions except as otherwise noted. 1: Gross Margin defined as Revenue less Cost of Revenue, as a percentage of Revenue. 2: Adj. EBITDA Margin represents Adjusted EBITDA as a percentage of Revenue. INOV Q4 2017 Earnings Presentation Supplement (2.20.18) v1.0.0 FY 2017 FY 2017 5 i W M inovalon Revenue and Adjusted EBITDA in-line with prior guidance, up 5% and 9% year-over- year, respectively Strong market adoption of the Inovalon ONE ™M Platform Signed multi-year engagements with multiple national health plans, state and regional players Expanded gross margin by 360 bps, driven by favorable product mix and pricing, and technology-enabled efficiency initiatives Expanded Adjusted EBITDA margin by 90 bps, consistent with guidance, while increasing investments in innovation and sales & marketing Total annualized revenue from new business signings increased by 45% and average revenue per opportunity increased by 54% versus 2016 Significant investments in platform innovation - including modularity, connectivity, compute power and cloud infrastructure, and enhanced data visualization Ⓒ2018 by Inovalon. All rights reserved.

View entire presentation